Difference between revisions of "Pimitespib (Jeselhy)"
Jump to navigation
Jump to search
m (Jwarner moved page Pimitespib (TAS-116) to Pimitespib (Jeselhy): PMDA approval) |
m |
||
| Line 2: | Line 2: | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pimitespib NCI Drug Dictionary]: A specific inhibitor of heat shock protein 90 (Hsp90) subtypes alpha and beta, with potential antineoplastic and chemo/radiosensitizing activities. Upon oral administration, Hsp90alpha/beta inhibitor TAS-116 specifically binds to and inhibits the activity of Hsp90 alpha and beta; this results in the proteasomal degradation of oncogenic client proteins, which inhibits client protein dependent-signaling, induces apoptosis, and inhibits the proliferation of cells overexpressing HSP90alpha/beta. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pimitespib NCI Drug Dictionary]: A specific inhibitor of heat shock protein 90 (Hsp90) subtypes alpha and beta, with potential antineoplastic and chemo/radiosensitizing activities. Upon oral administration, Hsp90alpha/beta inhibitor TAS-116 specifically binds to and inhibits the activity of Hsp90 alpha and beta; this results in the proteasomal degradation of oncogenic client proteins, which inhibits client protein dependent-signaling, induces apoptosis, and inhibits the proliferation of cells overexpressing HSP90alpha/beta. | ||
| − | == | + | ==Diseases for which it is used== |
| − | + | *[[Gastrointestinal stromal tumor]] | |
| − | |||
==Also known as== | ==Also known as== | ||
| Line 14: | Line 13: | ||
[[Category:Hsp90 inhibitors]] | [[Category:Hsp90 inhibitors]] | ||
| − | [[Category:Gastrointestinal stromal tumor medications | + | [[Category:Gastrointestinal stromal tumor medications]] |
[[Category:PMDA approved drugs]] | [[Category:PMDA approved drugs]] | ||
Revision as of 17:35, 6 September 2022
Mechanism of action
From the NCI Drug Dictionary: A specific inhibitor of heat shock protein 90 (Hsp90) subtypes alpha and beta, with potential antineoplastic and chemo/radiosensitizing activities. Upon oral administration, Hsp90alpha/beta inhibitor TAS-116 specifically binds to and inhibits the activity of Hsp90 alpha and beta; this results in the proteasomal degradation of oncogenic client proteins, which inhibits client protein dependent-signaling, induces apoptosis, and inhibits the proliferation of cells overexpressing HSP90alpha/beta.
Diseases for which it is used
Also known as
- Code name: TAS-116
- Brand name: Jeselhy